Kari B Wisinski

14PUBLICATIONS
107CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|May 04, 2026
Safety and immunogenicity of a tri-antigen vaccine targeting IGFBP-2, HER2, and IGF-IR in participants with non-metastatic breast cancer.

|Mar 26, 2026
Integrated Multiomic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast Cancer.

Ang Gao, Parth H Khatri, Gui Ma

|Oct 17, 2025
The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404).

Mamta Parikh, Nataliya V Uboha, Naoko Takebe

|May 14, 2025
Stromal Versican Accumulation and Proteolysis Regulate the Infiltration of CD8+ T Cells in Breast Cancer.

Philip B Emmerich, Tonela Qyli, Katherine A Johnson

|Mar 04, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.

Roisin M Connolly, Victoria Wang, David M Hyman

|May 19, 2023
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.

Kevin Kalinsky, Melissa K Accordino, Codruta Chiuzan

Pageof 3

Frequent Collaborators

3 joint publications

Amye J Tevaarwerk

3 joint publications

David R Patton

3 joint publications

Lisa M McShane

3 joint publications

Stanley R Hamilton